drugset / Trial / NCT00004665

Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus

NCT00004665

Treatment

Summary

OBJECTIVES: I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.

Timeline

Start
1995-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified Oral